<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156089</url>
  </required_header>
  <id_info>
    <org_study_id>140120</org_study_id>
    <secondary_id>14-AA-0120</secondary_id>
    <nct_id>NCT02156089</nct_id>
  </id_info>
  <brief_title>Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) Trial</brief_title>
  <official_title>Neuroimaging Omega-3 and Reward in Adults With ADHD (NORAA) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - People with attention-deficit hyperactivity disorder (ADHD) often have problems with
      motivation and rewards. . Omega-3 fats have helped symptoms of ADHD improve in children.
      Researchers want to learn more about the brain activity of people with ADHD and see how
      taking omega-3 fats might help.

      Objective:

      - To learn more about how omega-3 fats affect brain activity and ADHD symptoms.

      Eligibility:

      - Adults age 18 55 with ADHD symptoms.

      Design:

        -  Participants will be screened with medical history and review of medical records.

        -  For study visit 1, participants will have a medical examination and be interviewed to
           confirm they have ADHD. They will have an IQ test and give blood and urine samples.
           Height, weight, and blood pressure will be measured. They will also need to sign consent
           to agree to take part in the study. They will be asked to complete a food diary for 4
           days

        -  For visit 2, participants will give a blood sample. They will complete questionnaires
           about their mood and ADHD symptoms.. They may give a blood or saliva sample for genetic
           testing.

        -  Participants will have a magnetic resonance imaging (MRI) scan. They will lie on a table
           that slides in and out of a metal cylinder. It makes loud noises; participants will get
           earplugs. This scan examines the structure of the brain.

        -  Participants will have a functional MRI scan. This scan measures the function of the
           brain while the volunteer is performing tasks in the scanner. They will stop ADHD
           medications 48 hours before this scan.

        -  Participants will receive key-lime flavored omega-3 smoothie mix or placebo to takeevery
           day

        -  For visit 3, participants will give blood samples and complete questionnaires.

        -  For visit 4, participants will be weighed and have a blood test and MRI scans as per
           before. They will repeat the questionnaires and will guess whether they received the
           omega-3 or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:

      Both attention deficit hyperactivity disorder (ADHD) and addictive behaviors have been
      persistently related to impaired reward-related processes in the ventral striatum as
      evidenced by functional magnetic resonance imaging studies (fMRI). These impairments
      characterized by decreased BOLD activation are thought to be linked to dopamine pathways
      including decreased D2 receptor function. Omega-3 highly unsaturated fatty acids (HUFAs) are
      critical for cell-signaling among other complex functions throughout the central nervous
      system. Animal models have demonstrated that depriving animals of the omega-3 DHA in utero
      significantly decreases the density of ventral striatal D2- like receptors and furthermore
      depletes dopamine in the nucleus acumens by 40-60%. The behavioral profile of animals
      subjected to dietary induced deficiencies of omega-3 reflect decreased goal-directed behavior
      and increased goal-irrelevant activity, hyperactivity, increased anxiety and reduced behavior
      flexibility. Abnormally low levels of omega-3 HUFAs have been persistently reported in the
      erythrocytes of both children and adults with ADHD while supplementation with omega-3 HUFAs
      was found in a meta-analysis of 10 clinical trials to improve symptoms of ADHD. However, to
      date no one has tested the potential mediating effects of omega-3 supplementation in
      reward-related processes in adults with ADHD using neuroimaging techniques. There is hence a
      need to research the potential treatment effects of omega-3 on assessments of brain function.
      Therefore, the primary objective of this study is to test the effects of omega-3 intervention
      (compared to a placebo) in increasing ventral striatal activation during the monetary
      incentive delay (MID) task. Secondary objectives include collecting neuroimaging data and
      standardized questionnaires measuring, mood, quality of life and symptoms of ADHD.

      Study Population:

      150 adults, other-wise healthy, aged 18-55 with ADHD.

      Design:

      The active group will be stratified according to age and sex to either an active intervention
      group receiving (1) 3000 mg of omega-3 HUFA smoothie or a placebo group (2) 3000 mg of
      smoothie macadamia nut oil for 16 weeks. After enrollment and baseline testing, active
      participants will be randomized to either the treatment or placebo group and instructed to
      begin consumption of assigned emulsions. Randomized participants will be assessed at
      baseline, 1 month, 8 weeks, and 16 weeks.

      Outcome Measures:

      The primary outcome assessments will measure ventral-striatum activation during the MID task.
      Secondary objectives include: structural MRI, symptoms of ADHD using the Conner s Adult ADHD
      Rating Scales; negative affective symptoms; endocannabinoid levels and weight change.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>June 4, 2014</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>To test if omega-3 HUFA intervention results in greater ventral-striatal activation during a reward task in adults with ADHD compared to a placebo group between baseline and follow up at 16 weeks.</measure>
    <time_frame>baseline and afte 15 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">63</enrollment>
  <condition>Attention Deficit Disorder</condition>
  <condition>Attention Deficit Hyerpactivity Disorder</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Highly unsaturated omega-3 fatty acids</intervention_name>
    <description>Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Participants will be 18 or over and up to 55 years old.

          -  In general good health.

          -  Body Mass Index (BMI) between 18 and 35.

          -  Able to come to the NIH clinical center for each of their scheduled appointments for
             the duration of the study and have a working phone number.

          -  Able to understand the consent form and provide written informed consent.

          -  Have an IQ of 70 or greater as assessed by the WASI for fast IQ testing (a score of
             less than this is considered to have global intellectual disability - classified in
             DSM-IV as mental retardation). There are often issues around the ability to give
             informed consent in adults with global intellectual disability.

          -  Meet DSM diagnostic criteria for ADHD as assessed by the CAADID Conners Adult ADHD
             Diagnostic Interview for DSM-IV.

          -  Have significant symptoms of ADHD despite concurrent pharmacological and psychological
             therapies as assessed by the Connors Adult ADHD rating scale (CAARS) (as assessed at
             telephone screen).

          -  Be willing to have a 48hour wash-out of stimulant medication prior to both baseline
             and follow-up scans.

          -  Willing to stop all nutritional supplements including omega-3 fats.

          -  Willing to stop eating seafood for the study duration of 16 weeks.

          -  Be willing to have 2 MRI scanning sessions.

          -  People who are willing to take the smoothie emulsion every day for 16 weeks.

        EXCLUSION CRITERIA:

          -  Any medical illness or treatment that in the view of the investigators would
             compromise participation in research or participant safety, as determined by medical
             history, physical examination, laboratory tests (see details under Screening measures
             below), including, but not limited to:

          -  Unstable medical conditions requiring immediate intervention.

          -  Unstable or rapidly progressive neurological diseases.

          -  History hemorrhagic or ischemic stroke within the last 3 months.

          -  Known heart disease.

          -  Hypertension.

          -  Asthma

          -  If the participant is related to the study investigator or their superior,
             subordinate, or immediate family member.

          -  HIV positive.

          -  Significant dietary limitations:

        Allergy, hypersensitivity, or intolerance to fish oils or omega-3 fats which are found in
        fish..

          -  Allergy, hypersensitivity, or intolerance to Macadamia nuts or any nuts such as
             almonds, walnuts, pecans, peanuts, etc.

          -  Pregnancy or breastfeeding (by urine pregnancy test; self-report).

          -  Reported consumption of fish and seafood three or more times per week within the last
             three months.

          -  Regular consumption of omega-3 supplements (e.g., cod liver oil, borage oil, fish oil
             or evening primrose oil) , defined as an average of 250 mg/day of omega-3 HUFAs over
             the previous 3 months.

          -  Severe alcohol or substance use disorder according to the AUDIT.

          -  Acute intoxication or withdrawal from alcohol or other CNS active substances to the
             extent that they may impair capacity to provide informed consent or participate in
             research.

          -  Some neuropsychiatric disorders are either so rare or associated with such profound
             alterations of brains structure and function that they will be excluded. This includes
             a diagnosis of severe Bipolar disorders or Axis 1 psychotic disorder assessed by SCID,
             including schizophrenia, psychosis NOS, autism, substance dependence; dementia, eating
             disorder.

          -  Cognitive impairment severe enough to preclude informed consent or valid responses on
             self-report questionnaires.

          -  Behavioral instability significant enough to impair ability for consent and
             participation.

          -  Participation in other research studies that in the opinion of the investigators would
             interfere with study outcomes or study compliance.

          -  On any of the following medications: Atomoxetine (Strattera), bupropion (Wellbutrin),
             tricyclic antidepressants (imipramine), alpha adrenergic agonists (clonidine,
             guanfacine) or modafinil (Provigil) depending whether dose interferes with scan and
             whether or not patient can stay on same dose throughout study.

          -  Use of non-steroidal anti-inflammatory drugs (NSAIDs), dalteparin, dipyrdamole,
             enoxaparin, ticlopedine, more than once per week within the last three months.

          -  Living situation unsuitable for the storage or use of intervention materials.

        MRI Exclusion Criteria:

          -  Have ferromagnetic objects in their bodies, which might be adversely affected by MRI
             (e.g., surgical clips, metal fragments in or near brain, eye or blood vessels, cardiac
             or neurological pacemaker, cochlear or eye implant). Any doubt about presence of these
             objects will result in exclusion from this study.

          -  Extreme claustrophobia.

          -  Left-handed individuals.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph R Hibbeln, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2014-AA-0120.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Bondi CO, Taha AY, Tock JL, Totah NK, Cheon Y, Torres GE, Rapoport SI, Moghaddam B. Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency. Biol Psychiatry. 2014 Jan 1;75(1):38-46. doi: 10.1016/j.biopsych.2013.06.007. Epub 2013 Jul 25.</citation>
    <PMID>23890734</PMID>
  </reference>
  <reference>
    <citation>Zimmer L, Delion-Vancassel S, Durand G, Guilloteau D, Bodard S, Besnard JC, Chalon S. Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J Lipid Res. 2000 Jan;41(1):32-40.</citation>
    <PMID>10627499</PMID>
  </reference>
  <reference>
    <citation>Zimmer L, Delpal S, Guilloteau D, AÃ¯oun J, Durand G, Chalon S. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Lett. 2000 Apr 21;284(1-2):25-8.</citation>
    <PMID>10771153</PMID>
  </reference>
  <verification_date>April 9, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fMRI</keyword>
  <keyword>Reward Processing</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Omega-3 Fatty Acids</keyword>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

